GMAB
GENMAB A/SFigures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | Not reported | 12.8% | — |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | Not reported | 12.2% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | Not reported | 12.5% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | 83.8% | -1.4% | 14 / 54 |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | 72.3% | 0.6% | 2 / 38 |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 0.0% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -4.1% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 70.7% | — |
Operating margin Operating income as a share of revenue. | Not reported | -15.3% | — |
Net margin Net income as a share of revenue. | Not reported | -13.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -2.0% | — |
Return on equity Net income divided by shareholder equity. | 21.4% | -14.2% | 23 / 164 |
Return on assets Net income divided by total assets. | 17.1% | -9.5% | 15 / 188 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -6.1% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Annual financials
| Fiscal year | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | — | — | DKK 5.37B | DKK 3.02B | DKK 2.37B |
| Operating income | — | — | DKK 2.64B | DKK 1.38B | DKK 1.34B |
| Net income | DKK 7.84B | DKK 4.35B | DKK 2.17B | DKK 1.47B | DKK 1.10B |
| EPS (diluted) | DKK 121.36 | DKK 66.02 | DKK 34.03 | DKK 23.73 | DKK 17.77 |
| Operating cash flow | DKK 7.77B | DKK 7.38B | DKK 1.33B | DKK 1.01B | DKK 1.59B |
| Capital expenditure | — | — | DKK 79.00M | DKK 72.00M | DKK 89.00M |
| Free cash flow | — | — | DKK 1.25B | DKK 943.00M | DKK 1.50B |
| Total assets | DKK 45.81B | DKK 35.29B | DKK 15.14B | DKK 8.46B | — |
| Shareholder equity | DKK 36.70B | DKK 31.61B | DKK 14.05B | DKK 8.01B | DKK 6.27B |
| Cash | — | — | DKK 3.55B | DKK 533.00M | DKK 1.35B |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Amounts are in DKK, as the company reports them. Nothing here is converted to dollars, so these figures cannot be compared directly against a company reporting in another currency. Margins, returns and other ratios are unaffected.
Source
Figures come from GENMAB A/S’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 20-F filed Feb 17, 2026. View filings on EDGAR.